Overview

A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

Status:
Recruiting

Trial end date:
2024-08-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to assess the safety and tolerability of a single dose of LY3938577 in healthy participants and participants with Type 2 Diabetes Mellitus (T2DM) (Part A) and multiple doses of LY3938577 in participants with T2DM (Part B). The study will last approximately 6 weeks for Part A and approximately 10 weeks for Part B respectively.

Phase:

Phase 1

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Insulin